Cadila Healthcare Limited Exemestane Export Data — India (DGFT 2022–2026)

Name: Cadila Healthcare Limited Exemestane Export Records India — #8 Exporter, 4 Shipments, $200.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Exemestane

India Pharmaceutical Trade Intelligence

$14.5M87 Suppliers57 CountriesHS 30049049

ExportsIndia → UNITED STATES39.3%India → BRAZIL12.2%

ImportsUNITED STATES → India$163.0K ITALY → India$146.4K

#1 Supplier: INTAS PHARMACEUTICALS #1 Buyer: CARDINAL HEALTH

Cadila Healthcare Limited — Exemestane Exporter #8 | $200.0K Trade Value | TransData Nexus | TransData Nexus

Cadila Healthcare Limited — Exemestane Exporter Profile

Indian Pharmaceutical Exporter · #8 for Exemestane · $200.0K export value · DGFT Verified

Cadila Healthcare Limited is the #8 Indian exporter of Exemestane with $200.0K in export value and 4 verified shipments. Cadila Healthcare Limited holds a 1.4% market share in Exemestane exports across 1 countries. The company exports 41 pharmaceutical products worth $34.9M across 17 therapeutic categories.

Cadila Healthcare Limited — Exemestane Export Profile: Buyers & Destinations

Cadila Healthcare Limited Exemestane export treemap — buyers and destination countries | TransData Nexus

Where Does India Export Exemestane?

Country	Value	Shipments	Share
UNITED STATES	$4.2M	83	37.3%
NETHERLANDS	$1.7M	80	15.2%
UNITED KINGDOM	$1.4M	27	12.1%
GERMANY	$882.2K	25

Who Are the Top Buyers of Exemestane from India?

Buyer	Country	Value	Orders
CARDINAL HEALTH	UNITED STATES	$800.0K	16
BROCACEF NL HUB	NETHERLANDS	$699.9K	20
FIEGE HEALTHCARE LOGISTICS GMBH	GERMANY	$604.5K	19
AUROBINDO PHARMA USA., INC,	UNITED STATES	$450.0K	9
CIPLA USA INC UPS SUPPLY CHAIN SOLU	UNITED STATES	$450.0K	9
XXDUSXXHARXXCEUXXCALXXUSAXXNC	UNITED STATES	$300.0K	6
ZYDUS PHARMACEUTICALS USA INC	UNITED STATES	$250.0K	5
M P L	UNITED KINGDOM	$200.0K	4
AUROBINDO PHARMA USA INC	UNITED STATES	$150.0K	3
AUROBINDO PHARMA USA., INC	UNITED STATES	$150.0K	3

India's Exemestane is purchased by 196 buyers worldwide. The top buyer is CARDINAL HEALTH (UNITED STATES), followed by BROCACEF NL HUB and FIEGE HEALTHCARE LOGISTICS GMBH.

How Does Cadila Healthcare Limited Compare to Nearest Exemestane Exporters?

Exporters ranked immediately above and below #8 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
9	INTAS PHARMACEUTICALS LTD	$355.9K	13	4	$27.4K
7	ZYDUS LIFESCIENCES LIMITED	$300.0K	6	1	$50.0K
8	CADILA HEALTHCARE LIMITED ★	$200.0K	4	1	$50.0K
10	JODAS EXPOIM PRIVATE LIMITED	$136.6K	6	1	$22.8K
11	CELON LABORATORIES PRIVATE LIMITED	$119.7K	10	4	$12.0K

Cadila Healthcare Limited ranks #8 among 87 Indian Exemestane exporters. Average shipment value of $50.0K compared to the market average of $124.9K. The closest competitors by value are INTAS PHARMACEUTICALS LTD and ZYDUS LIFESCIENCES LIMITED.

Which Indian Ports Ship Exemestane Exports?

Port	Shipments	% Share
SAHAR AIR CARGO ACC (INBOM4)	314	20.5%
DELHI AIR CARGO ACC (INDEL4)	273	17.8%
SAHAR AIR	256	16.7%
DELHI AIR	128	8.3%
Bombay Air Cargo	62	4.0%
MUNDRA SEA (INMUN1)	52	3.4%
MUNDRA SEA	51	3.3%
AHEMDABAD AIR ACC (INAMD4)	50	3.3%

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Exemestane Exports

The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Zydus. The escalating conflict in the Middle East has disrupted key maritime routes, particularly the Red Sea and Suez Canal, leading to longer transit times and increased freight costs. Major carriers have suspended or restricted transits, extending transit times by 10–20 days and raising freight rates by 40–50% on key India–Europe routes. (livemint.com) This situation poses significant challenges for time-sensitive pharmaceutical shipments, especially temperature-sensitive medicines. (economictimes.indiatimes.com)

Conversely, U.S.–China trade tensions have prompted the U.S. to impose tariffs on Chinese pharmaceutical imports, creating an opportunity for Indian exporters to fill the supply gap. However, the U.S. has also introduced tariffs on Indian imports, including a 25% "reciprocal" tariff, followed by an additional 25% penalty tied to India's continued imports of Russian oil, bringing the total duty to 50%. (en.wikipedia.org) While pharmaceuticals are currently exempt, the potential for future tariffs necessitates strategic planning.

In the European Union, compliance with the Falsified Medicines Directive (FMD) is crucial. The FMD mandates stringent serialization and traceability requirements to prevent counterfeit medicines from entering the supply chain. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

Maintaining compliance with international regulatory standards is paramount for Indian pharmaceutical exporters. The U.S. FDA, WHO, and EU Good Manufacturing Practice (GMP) guidelines set stringent quality benchmarks. Any lapses can lead to import alerts, product recalls, or facility shutdowns. For instance, in 2019, Zydus's Moraiya facility received an Official Action Indicated (OAI) classification from the U.S. FDA, indicating that regulatory and/or administrative actions were recommended. (moneycontrol.com) Such events underscore the importance of robust quality assurance systems.

The evolving regulatory landscape demands continuous investment in compliance infrastructure. The EU's Falsified Medicines Directive and the U.S. Drug Supply Chain Security Act (DSCSA) require advanced serialization and traceability measures. Non-compliance can result in restricted market access, making adherence to these regulations imperative for exporters like Zydus.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Exemestane shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Cadila Healthcare Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 57+ countries, 196+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Exemestane

Exemestane

Cadila Healthcare Limited — Exemestane Exporter Profile

Cadila Healthcare Limited — Exemestane Export Profile: Buyers & Destinations

Where Does India Export Exemestane?

Who Are the Top Buyers of Exemestane from India?

What Is India's Total Exemestane Export Value and How Much Does Cadila Healthcare Limited Contribute?

What Is the Average Shipment Value for Cadila Healthcare Limited's Exemestane Exports?

How Does Cadila Healthcare Limited Compare to Other Indian Exemestane Exporters?

Regulatory Requirements: Exporting Exemestane to Key Markets

United States — FDA

United Kingdom — MHRA

How Does Cadila Healthcare Limited Compare to Nearest Exemestane Exporters?

Which Indian Ports Ship Exemestane Exports?

Geopolitical & Trade Policy Impact on Cadila Healthcare Limited's Exemestane Exports

Cadila Healthcare Limited — Regulatory Compliance & Quality Standards

About Cadila Healthcare Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Exemestane Export Data from Cadila Healthcare Limited

Exemestane Stats

Company Overview

Top Products by Cadila Healthcare Limited

Related Analysis

Need Detailed Export Data?

Data Source